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Context 
Increased incidence of postpartum hemorrhage is reported in a number of high 
resource settings since the 1990s.1  The increase appears unrelated to factors such as 
rising rates of caesarean section or increasing maternal age.1 Recent studies have 
investigated the association between antidepressant use at different stages of 
pregnancy and postpartum hemorrhage, with two studies demonstrating a 1.202, and 
1.45-fold3 increased risk of bleeding at delivery and another study4 reporting no 
association. Selective serotonin uptake inhibitors (SSRIs) are increasingly prescribed 
and may impair platelet function by blocking serotonin uptake into platelets and 
impairing their homeostatic ability. The authors in the current study aimed to assess 
the association between exposure to antidepressants, particularly SSRIs, at the time of 
delivery and postpartum hemorrhage. 
 
Methods 
This US study used nationwide Medicaid data comprising a 2000-2007 cohort of 
pregnancies among low income women. The authors restricted their population to 
inpatients/outpatients with ICD9 diagnoses of mood and anxiety disorders. Exposure 
to antidepressants categorized as serotonin reuptake inhibitors or non-serotonin 
reuptake inhibitors was based on prescription dispensing date and supply relative to 
delivery date. Women exposed to more than one drug type were excluded from 
analysis. Four mutually exclusive exposure groups were assessed relative to delivery: 
current exposure (women with a supply date overlapping the delivery date), recent 
exposure (at least one day in the month prior), past exposure (supply ending 1-5 
months pre-delivery) and unexposed (no supply of antidepressants in the last five 
months). Postpartum hemorrhage was identified using ICD9 coding during the 
admission for delivery (inpatients), or within three days of the delivery date 
(outpatient deliveries). Confounders assessed included: year, age, race, multiple 
pregnancy, coagulopathies, diabetes, proxies of mood disorder severity and 
comorbidity, indications for antidepressants, use of psychotropic drugs, and other 
drugs associated with bleeding risk. Generalized estimating equations were used to 
identify relative risks (and risk differences) for postpartum hemorrhage among 
women exposed and unexposed to antidepressants.  
 
Findings 
Of the 106,000 pregnant women with diagnoses for mood or anxiety disorders, 15.1% 
had a supply of antidepressants overlapping their delivery date including 12,710 
(12%) with exposure only to serotonin reuptake inhibitors (SRI) and 1,495 (1.4%) 
with exposure only to non-serotonin reuptake inhibitors (non-SRI).  The risk of 
postpartum hemorrhage was 2.8% among women with mood/ anxiety disorders but no 
exposure to antidepressants and ranged from 2.5-4.0% in the groups exposed to SRIs 
and non-SRIs. Compared with no exposure, women with current exposure to SRI had 
a 1.47-fold increased risk of postpartum hemorrhage (95% CI 1.33-1.62) and women 
with current non-SRI exposure had a 1.39-fold increased risk (1.07-1.81).  Recent SRI 
exposure and past non-SRI exposure showed borderline associations with postpartum 
hemorrhage with adjusted relative risks of 1.19 (1.03-1.38) and 1.26 (1.00-1.59) 
respectively.  
 
Commentary 
In the context of differing published findings, the authors of this study sought to 
harness the strengths of nationwide data to investigate differing windows of exposure 
to antidepressants in pregnancy and subsequent postpartum hemorrhage. 
 
While strengths of using population-based data include high generalisability of 
findings, the restriction to low-income women on single therapy potentially negates 
this advantage.  Further, the study is limited by likely under-ascertainment of women 
with mood or anxiety disorders in pregnancy, measurement of antidepressant 
exposure based on prescription date and supply (versus use) and lack of data on 
severity of postpartum hemorrhage.  
 
The authors appropriately conclude that potential confounding by unmeasured factors 
cannot be ruled out. There are some important confounders that this study could not 
assess including obesity, parity and previous postpartum hemorrhage. Notably the 
Salkeld study4 accounted for previous hemorrhage and reported no statistically 
significant association of SSRI use in the past 30 days with postpartum hemorrhage. 
 
The study indicates that there may be one excess case of postpartum hemorrhage for 
every 80 to 100 women using antidepressants near the time of delivery. This provides 
further reason to counsel women of reproductive age who commence SSRIs about 
their possible effects in pregnancy. In addition to postpartum hemorrhage, SSRIs have 
been described to increase the risk of miscarriage, fetal anomalies and autism. 
Discontinuation at any stage of pregnancy needs to be based on balancing the risks of 
discontinuing or substituting antidepressants against other risks, which at birth include  
postpartum hemorrhage. In this context, further studies that can determine the 
association with severe hemorrhage are warranted.  
 
Taken with findings from other studies, it would be reasonable to take into account 
recent history of antidepressant use as a potential risk factor for postpartum 
hemorrhage when counseling women about where to deliver. The consistent increase 
in incidence of postpartum hemorrhage across multiple international locations is 
unlikely to be attributable entirely to antidepressant use, but this may be one of a 
myriad of factors that contribute to the increase.  
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